initiated coverage on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a research note released on Wednesday. The brokerage issued a buy rating and a $23.00 price target on the stock.

A number of other equities analysts also recently weighed in on the stock. HC Wainwright reaffirmed a buy rating and set a $23.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a buy rating to a hold rating in a research note on Tuesday, November 7th. Royal Bank Of Canada reaffirmed a buy rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Robert W. Baird reaffirmed a buy rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, Jefferies Group LLC reaffirmed a buy rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Karyopharm Therapeutics has a consensus rating of Buy and an average price target of $17.33.

Karyopharm Therapeutics (NASDAQ KPTI) traded up $0.22 during mid-day trading on Wednesday, reaching $11.39. 185,532 shares of the company were exchanged, compared to its average volume of 242,579. Karyopharm Therapeutics has a 12 month low of $7.48 and a 12 month high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. analysts anticipate that Karyopharm Therapeutics will post -2.58 EPS for the current year.

WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dailypolitical.com/2017/11/16/karyopharm-therapeutics-inc-kpti-receives-new-coverage-from-analysts-at.html.

In related news, SVP Christopher Brett Primiano sold 4,958 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total value of $55,777.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mansoor Raza Mirza sold 2,882 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the sale, the director now owns 2,882 shares in the company, valued at approximately $31,702. The disclosure for this sale can be found here. Insiders have sold 15,653 shares of company stock valued at $174,728 in the last three months. 14.71% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of the company. Iguana Healthcare Management LLC boosted its stake in shares of Karyopharm Therapeutics by 33.3% during the 3rd quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock worth $4,392,000 after acquiring an additional 100,000 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Karyopharm Therapeutics by 21.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 140,360 shares of the company’s stock worth $1,542,000 after acquiring an additional 24,324 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Karyopharm Therapeutics by 753.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock worth $3,342,000 after acquiring an additional 271,208 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Karyopharm Therapeutics by 16.4% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock worth $5,600,000 after acquiring an additional 72,000 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in shares of Karyopharm Therapeutics by 396.0% during the 3rd quarter. Nationwide Fund Advisors now owns 105,664 shares of the company’s stock worth $1,160,000 after acquiring an additional 84,362 shares during the last quarter. Institutional investors and hedge funds own 59.23% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.